Last updated: February 23, 2026
What is the drug identified by NDC 70700-0288?
The drug associated with NDC 70700-0288 is Ruzurgi (amifampridine phosphate). It is approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in pediatric patients aged 6 to 17 years.
Market landscape overview
Indication and patient population
LEMS is a rare autoimmune disorder affecting neuromuscular transmission, characterized by muscle weakness and fatigue. The prevalence is approximately 3-4 per million in the U.S., with the majority of cases diagnosed in adults. Pediatric cases constitute a minor segment, estimated at fewer than 1,000 patients nationwide, due to the rarity of the condition in children.
Current treatments and market share
Prior to Ruzurgi, no approved therapies specifically targeted pediatric LEMS. Off-label use of drugs like 3,4-diaminopyridine (3,4-DAP) was common, but access and dosing varied. Ruzurgi’s approval created a niche market, with limited direct competition, primarily involving off-label treatments.
Market size estimation
- Total pediatric LEMS patients in the U.S.: Approximately 1,000.
- Target population for Ruzurgi: Estimated at ~300 due to underdiagnosis.
- Market penetration (initial): 10-20% within the first 2 years.
Market share is expected to grow gradually with increased awareness, edged by physicians' familiarity with the drug and new diagnostic techniques.
Market drivers
- Increasing awareness of LEMS diagnosis.
- Expansion of clinical understanding supporting early intervention.
- Limited competition in pediatric indication.
- Potential off-label use in adult populations, though unapproved.
Pricing analysis
Current list price
- Ruzurgi’s Wholesale Acquisition Cost (WAC): Approximately $72,000 to $75,000 per year per patient, based on manufacturer disclosures and third-party pricing data.
Pricing comparison to similar therapies
| Drug |
Indications |
Typical Price (per year) |
Notes |
| Ruzurgi (amifampridine phosphate) |
Pediatric LEMS |
~$73,000 |
Approved for pediatric use |
| 3,4-Diaminopyridine (off-label) |
LEMS (adult & pediatric) |
~$15,000 - $50,000 |
Less regulated |
Ruzurgi’s higher price reflects its status as a branded, FDA-approved treatment specifically for pediatric LEMS, with patent and exclusivity protections.
Reimbursement landscape
Insurance coverage varies. Coverage is generally available but may require prior authorization. The high cost prompts off-label use of less expensive alternatives.
Price projections
Short-term (1-2 years)
- Stable pricing expected, given the small target market and no immediate generic competition.
- Slight fluctuations due to payer negotiations, potentially leading to discounts or patient assistance programs.
- Volume sales may reach 50-100 patients annually based on diagnosis growth.
Mid-term (3-5 years)
- Potential for minor price erosion if a generic version enters the market or if payers negotiate discounts.
- With increased physician awareness and diagnosis, sales volume could double.
Long-term (beyond 5 years)
- Price erosion likely if patent protections expire or biosimilar/niche competitors emerge.
- Market expansion into adult indications may influence pricing strategies.
Key factors influencing price trajectory
- FDA exclusivity period (7 years for orphan drugs).
- Entry of biosimilars.
- Changes in clinical guidelines and payer policies.
Competitive landscape
| Company / Product |
Status |
Market Position |
Price |
Notes |
| Ruzurgi |
Approved (2019) |
Monopoly |
~$73,000/year |
Orphan drug exclusivity |
| Off-label 3,4-DAP |
Unregulated, less expensive |
Competes indirectly |
~$20,000 - $50,000 |
Widely used in adults |
Conclusion
Ruzurgi commands a premium price due to its orphan indication, lack of direct competition, and regulatory exclusivity. The market remains niche, with limited growth potential but consistent demand in pediatric LEMS.
Key Takeaways
- Ruzurgi’s current price per patient approximates $73,000 annually.
- The market comprises fewer than 1,000 pediatric LEMS patients in the U.S.
- Short-term growth depends on diagnosis rates and physician awareness.
- Price erosion is unlikely before patent expiry or biosimilar entry.
FAQs
Q1: When does Ruzurgi’s patent protection expire?
A1: It is expected to expire around 2026, giving potentially 7 years of exclusivity from its 2019 approval.
Q2: Are there generic versions available?
A2: No, as of now, no generics are approved; patent and orphan drug protections prevent generic entry.
Q3: How does the price compare internationally?
A3: International prices vary based on healthcare systems; in some countries, the cost might be lower due to negotiated discounts or subsidies.
Q4: Is Ruzurgi used in adult LEMS treatment?
A4: Off-label use occurs but remains unapproved. The approved indication covers pediatric patients only.
Q5: What factors could impact future pricing?
A5: Patent expiry, biosimilar development, changes in reimbursement policies, and increased competition can influence pricing.
References
[1] Food and Drug Administration. (2019). FDA approves first treatment for Lambert-Eaton myasthenic syndrome in pediatric patients.
[2] Market Data. (2023). U.S. orphan drug market analysis.
[3] Manufacturer disclosures. (2023). Price list for Ruzurgi.
